Biodexa Historical Financial Ratios

BDRX Stock

5.62 0.69 14.00%

Biodexa Pharmaceticals is presently reporting on over 91 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 0.34 or Days Sales Outstanding of 290 will help investors to properly organize and evaluate Biodexa Pharmaceticals financial condition quickly.

Quick Ratio Current Ratio

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biodexa Pharmaceticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.

About Biodexa Financial Ratios Analysis

Biodexa PharmaceticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Biodexa Pharmaceticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Biodexa financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Biodexa Pharmaceticals history.

Biodexa Pharmaceticals Financial Ratios Chart

At this time, Biodexa Pharmaceticals' Days Sales Outstanding is fairly stable compared to the past year. Stock Based Compensation To Revenue is likely to rise to 0.08 in 2024, whereas Price To Sales Ratio is likely to drop 4.15 in 2024.

Price To Sales Ratio Ptb Ratio Days Sales Outstanding Book Value Per Share Days Payables Outstanding Cash Ratio

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Biodexa Pharmaceticals stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Biodexa Pharmaceticals sales, a figure that is much harder to manipulate than other Biodexa Pharmaceticals multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Most ratios from Biodexa Pharmaceticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Biodexa Pharmaceticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biodexa Pharmaceticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.At this time, Biodexa Pharmaceticals' Days Sales Outstanding is fairly stable compared to the past year. Stock Based Compensation To Revenue is likely to rise to 0.08 in 2024, whereas Price To Sales Ratio is likely to drop 4.15 in 2024.

	2021	2022	2023	2024 (projected)
Days Sales Outstanding	20.84	171.8	197.56	290.21
PTB Ratio	29.89	25.45	0.36	0.34

Days Sales Outstanding Ptb Ratio

Biodexa Pharmaceticals fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Average Inventory	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow
Price To Sales Ratio		0.8	-0.14	0.19	0.67	-0.38	-0.1	0.8	0.7	-0.38	0.21	0.09	-0.56	0.06	0.05	-0.72	-0.01	0.26	-0.72	-0.13	-0.05	-0.73	0.07	-0.42	-0.07	-0.51
Ptb Ratio	0.8		-0.34	-0.29	0.54	0.09	-0.27	1.0	0.83	0.09	-0.23	-0.18	-0.1	-0.21	0.26	-0.82	-0.12	-0.22	-0.38	-0.44	0.21	-0.4	-0.2	-0.32	-0.28	-0.67
Days Sales Outstanding	-0.14	-0.34		0.43	0.09	-0.39	0.32	-0.34	-0.55	-0.39	0.38	0.8	-0.32	0.38	-0.65	0.43	0.23	0.41	-0.07	0.35	-0.38	-0.06	0.37	-0.06	0.18	0.62
Book Value Per Share	0.19	-0.29	0.43		0.6	-0.97	0.23	-0.29	-0.45	-0.97	0.7	0.59	-0.87	0.58	-0.41	0.49	0.14	1.0	-0.63	0.81	-0.43	-0.63	0.58	-0.09	0.39	0.4
Free Cash Flow Yield	0.67	0.54	0.09	0.6		-0.7	-0.02	0.54	0.18	-0.69	0.36	0.36	-0.7	0.32	-0.16	-0.16	0.0	0.64	-0.85	0.42	-0.18	-0.85	0.32	-0.19	0.15	-0.2
Operating Cash Flow Per Share	-0.38	0.09	-0.39	-0.97	-0.7		-0.17	0.09	0.28	1.0	-0.66	-0.57	0.96	-0.56	0.35	-0.35	-0.13	-0.98	0.68	-0.7	0.38	0.68	-0.55	0.24	-0.31	-0.32
Capex To Depreciation	-0.1	-0.27	0.32	0.23	-0.02	-0.17		-0.27	-0.45	-0.17	0.42	0.08	-0.11	0.59	-0.49	0.19	0.83	0.22	-0.1	0.32	-0.86	-0.09	0.59	-0.06	0.45	0.35
Pb Ratio	0.8	1.0	-0.34	-0.29	0.54	0.09	-0.27		0.83	0.09	-0.23	-0.18	-0.1	-0.21	0.26	-0.82	-0.12	-0.22	-0.38	-0.44	0.21	-0.4	-0.2	-0.32	-0.28	-0.67
Ev To Sales	0.7	0.83	-0.55	-0.45	0.18	0.28	-0.45	0.83		0.28	-0.28	-0.39	0.08	-0.45	0.37	-0.89	-0.3	-0.39	-0.2	-0.66	0.4	-0.21	-0.44	-0.32	-0.3	-0.87
Free Cash Flow Per Share	-0.38	0.09	-0.39	-0.97	-0.69	1.0	-0.17	0.09	0.28		-0.67	-0.57	0.96	-0.56	0.35	-0.35	-0.13	-0.98	0.68	-0.7	0.39	0.68	-0.55	0.24	-0.31	-0.32
Roic	0.21	-0.23	0.38	0.7	0.36	-0.66	0.42	-0.23	-0.28	-0.67		0.41	-0.59	0.65	-0.54	0.21	0.04	0.71	-0.56	0.67	-0.5	-0.55	0.65	-0.12	0.73	0.25
Inventory Turnover	0.09	-0.18	0.8	0.59	0.36	-0.57	0.08	-0.18	-0.39	-0.57	0.41		-0.51	0.2	-0.56	0.31	0.11	0.59	-0.37	0.35	-0.42	-0.36	0.19	-0.15	0.28	0.43
Net Income Per Share	-0.56	-0.1	-0.32	-0.87	-0.7	0.96	-0.11	-0.1	0.08	0.96	-0.59	-0.51		-0.48	0.26	-0.17	-0.11	-0.9	0.65	-0.51	0.32	0.66	-0.49	0.4	-0.19	-0.23
Days Of Inventory On Hand	0.06	-0.21	0.38	0.58	0.32	-0.56	0.59	-0.21	-0.45	-0.56	0.65	0.2	-0.48		-0.69	0.33	0.26	0.58	-0.34	0.68	-0.45	-0.34	1.0	0.2	0.2	0.46
Payables Turnover	0.05	0.26	-0.65	-0.41	-0.16	0.35	-0.49	0.26	0.37	0.35	-0.54	-0.56	0.26	-0.69		-0.27	-0.26	-0.4	0.24	-0.37	0.55	0.24	-0.69	-0.11	-0.24	-0.3
Average Inventory	-0.72	-0.82	0.43	0.49	-0.16	-0.35	0.19	-0.82	-0.89	-0.35	0.21	0.31	-0.17	0.33	-0.27		0.09	0.43	0.3	0.59	-0.19	0.31	0.32	0.16	0.23	0.79
Capex To Revenue	-0.01	-0.12	0.23	0.14	0.0	-0.13	0.83	-0.12	-0.3	-0.13	0.04	0.11	-0.11	0.26	-0.26	0.09		0.14	-0.05	0.09	-0.83	-0.05	0.26	-0.31	0.13	0.22
Cash Per Share	0.26	-0.22	0.41	1.0	0.64	-0.98	0.22	-0.22	-0.39	-0.98	0.71	0.59	-0.9	0.58	-0.4	0.43	0.14		-0.68	0.79	-0.42	-0.67	0.57	-0.13	0.38	0.36
Pocfratio	-0.72	-0.38	-0.07	-0.63	-0.85	0.68	-0.1	-0.38	-0.2	0.68	-0.56	-0.37	0.65	-0.34	0.24	0.3	-0.05	-0.68		-0.47	0.3	1.0	-0.34	0.07	-0.29	0.31
Interest Coverage	-0.13	-0.44	0.35	0.81	0.42	-0.7	0.32	-0.44	-0.66	-0.7	0.67	0.35	-0.51	0.68	-0.37	0.59	0.09	0.79	-0.47		-0.33	-0.46	0.67	0.21	0.39	0.48
Capex To Operating Cash Flow	-0.05	0.21	-0.38	-0.43	-0.18	0.38	-0.86	0.21	0.4	0.39	-0.5	-0.42	0.32	-0.45	0.55	-0.19	-0.83	-0.42	0.3	-0.33		0.3	-0.45	0.29	-0.56	-0.29
Pfcf Ratio	-0.73	-0.4	-0.06	-0.63	-0.85	0.68	-0.09	-0.4	-0.21	0.68	-0.55	-0.36	0.66	-0.34	0.24	0.31	-0.05	-0.67	1.0	-0.46	0.3		-0.34	0.08	-0.28	0.31
Days Payables Outstanding	0.07	-0.2	0.37	0.58	0.32	-0.55	0.59	-0.2	-0.44	-0.55	0.65	0.19	-0.49	1.0	-0.69	0.32	0.26	0.57	-0.34	0.67	-0.45	-0.34		0.19	0.19	0.45
Income Quality	-0.42	-0.32	-0.06	-0.09	-0.19	0.24	-0.06	-0.32	-0.32	0.24	-0.12	-0.15	0.4	0.2	-0.11	0.16	-0.31	-0.13	0.07	0.21	0.29	0.08	0.19		-0.11	0.11
Roe	-0.07	-0.28	0.18	0.39	0.15	-0.31	0.45	-0.28	-0.3	-0.31	0.73	0.28	-0.19	0.2	-0.24	0.23	0.13	0.38	-0.29	0.39	-0.56	-0.28	0.19	-0.11		0.14
Ev To Operating Cash Flow	-0.51	-0.67	0.62	0.4	-0.2	-0.32	0.35	-0.67	-0.87	-0.32	0.25	0.43	-0.23	0.46	-0.3	0.79	0.22	0.36	0.31	0.48	-0.29	0.31	0.45	0.11	0.14

Click cells to compare fundamentals

Biodexa Pharmaceticals Account Relationship Matchups

Biodexa Pharmaceticals fundamentals Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Days Sales Outstanding	11.91	101.09	20.84	171.8	197.56	290.21
Capex To Depreciation	0.25	0.17	0.79	0.18	0.93	0.86
Ev To Sales	346.16	833.48	524.45	111.97	(10.09)	(9.58)
Roic	(0.54)	(1.65)	(0.74)	(3.1)	(1.62)	(1.7)
Payables Turnover	10.82	18.01	9.6	15.08	12.95	9.35
Sales General And Administrative To Revenue	5.7	14.45	5.1	6.5	11.4	9.3
Research And Ddevelopement To Revenue	11.64	47.07	8.05	7.31	10.67	16.57
Capex To Revenue	0.47	0.61	0.55	0.0887	0.69	1.18
Interest Coverage	(116.68)	(313.85)	(159.05)	(168.53)	(195.46)	(205.24)
Capex To Operating Cash Flow	(0.0492)	(0.0225)	(0.0533)	(0.008797)	(0.0385)	(0.0405)
Days Payables Outstanding	33.74	20.27	38.04	24.21	28.18	26.77
Income Quality	0.89	0.64	0.42	1.1	0.92	0.96
Roe	(0.47)	(3.3)	(0.52)	(2.42)	(1.51)	(1.59)
Ev To Operating Cash Flow	(35.96)	(30.74)	(50.45)	(11.1)	0.56	0.59
Return On Tangible Assets	(0.49)	(2.26)	(0.42)	(1.39)	(0.93)	(0.98)
Ev To Free Cash Flow	(34.27)	(30.06)	(47.9)	(11.01)	0.54	0.57
Net Debt To E B I T D A	0.51	0.33	1.64	0.3	0.77	1.05
Current Ratio	2.42	3.1	6.39	2.47	1.26	1.2
Receivables Turnover	30.64	3.61	17.52	2.12	1.91	1.82
Debt To Equity	0.19	0.0592	0.25	0.0159	0.0183	0.0174

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Biodexa Stock Analysis

When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Biodexa Historical Financial Ratios

About Biodexa Financial Ratios Analysis

Biodexa Pharmaceticals Financial Ratios Chart

Price To Sales Ratio

Ptb Ratio

Book Value Per Share

Biodexa Pharmaceticals fundamentals Correlations

Biodexa Pharmaceticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Biodexa Pharmaceticals fundamentals Accounts

Also Currently Popular

Additional Tools for Biodexa Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Cash Per Share	+ 1.0	Book Value Per Share
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Days Payables Outstanding	+ 1.0	Days Of Inventory On Hand
Pfcf Ratio	+ 1.0	Pocfratio
Net Income Per Share	+ 0.96	Operating Cash Flow Per Share

Cash Per Share	- 0.98	Free Cash Flow Per Share
Cash Per Share	- 0.98	Operating Cash Flow Per Share
Free Cash Flow Per Share	- 0.97	Book Value Per Share
Operating Cash Flow Per Share	- 0.97	Book Value Per Share
Cash Per Share	- 0.9	Net Income Per Share
Average Inventory	- 0.89	Ev To Sales